Author/Editor		Korošec, B; Drinovec, J; Mrhar, A; Urleb, U
Title		Pljučnica domačega okolja - od bolnika do družbe
Translated title		Community-acquired pneumonia - from patient to community
Type		članek
Source		Farm Vestn
Vol. and No.		Letnik 50, št. 1
Publication year		1999
Volume		str. 7-12
Language		slo
Abstract		Despite low incidence, community-acquired pneumonia is a lower respiratory tract infection of significanl clinical and social importance. The evaluation of the rate of occurrence of community-acquircd pneumonia was grounded on pooled offical epidemiological data for the whole region of Slovenia, a model region and a community. In Slovenia, community-acquired pneumonia is annually contracted by approximately 1% of the population. Hospitalisation due to a more severe clinical picture of the disease is required in every fourth patienl and in every fortieth patienl the discase has a fatal outcome. According to the therapeutic doctrine supported in the world as well as in Slovenia, we selected the most commonly prescribed antibiotic agents and evaluated them from the clinical and pharmacoeconomic aspect. Considering the distribution of pathogens causing community-acquired pneumonia and the efficacy of the selected antimicrobials, the evaluation results demonstrated that macrolide antibiotics were associated with the lowest cost of treatment. The highest total expenses involved in the treatment of community-acquired pneumonia resulted from hospitalisation and absence from work, rather than from the cost of a medicina product, medical examination or the diagnostic procedure.
Summary		Pljučnica domačega okolja (PDO) je kljub majhni incidenci s kliničnega in z družbenega vidika pomembna okužba spodnjih dihal. Na osnovi zbranih uradnih epidemioloških podatkov o pljučnici domačega okolja v Sloveniji, njeni modelni regiji in občini smo ocenili pogostnost pojavljanja te bolezni. V Sloveniji vsako leto za pljučnico domačega okolja zboli približno 1% prebivalstva. Vsak četrti bolnik je zdradi hujše klinične slike zdravljen bolnišnično, medtem ko vsak štirideseti bolnik s pljučnico domačega okolja umre. Glede na doktrino zdravljenja po svetu in v Sloveniji smo izbrali najpogosteje uporabljene antibiotike ter jih ovrednotili s kliničnega in s farmakoekonomskega stališča. Po porazdelitvi povzročiteljev pljučnic domačega okolja in učinkovitosti protimikrobnih zdravil so najnižji predvideni stroški zdravljenja pri makrolidnih antibiolikih. Največji delež v skupnih stroških zdravljenja pljučnice domačega okolja imata bolnišnično zdravljenje in odsotnost z dela, ne pa cena zdravila, niti stroški zdravniškega pregleda ali diagnostike.
Descriptors		COMMUNITY-ACQUIRED INFECTIONS PNEUMONIA EPIDEMIOLOGY ECONOMICS, PHARMACEUTICAL SLOVENIA ANTIBIOTICS